For the tens of millions of adults living with multivessel coronary artery disease, the duration of antiplatelet therapy after stenting has long been a calculated gamble — enough clot prevention without tipping into dangerous bleeding. New evidence from a major trial published in the New England Journal of Medicine may meaningfully shift how cardiologists calibrate that tradeoff for this higher-risk population.
The trial examined whether extending dual antiplatelet therapy (DAPT) — the standard combination of aspirin plus a P2Y12 inhibitor — beyond the conventional treatment window reduces major adverse cardiovascular events in patients with multivessel coronary artery disease. The study, appearing in NEJM Volume 395, focused specifically on this anatomically complex subgroup, which carries elevated residual ischemic risk compared to single-vessel disease. The investigators tracked rates of myocardial infarction, stroke, and cardiovascular death across extended versus standard-duration DAPT arms, finding that prolonged therapy was associated with meaningful reductions in ischemic endpoints within this cohort.
The broader DAPT literature has been contested for over a decade. Landmark trials like DAPT, PEGASUS-TIMI 54, and TWILIGHT have collectively established that extension benefits are not uniform — patient anatomy, bleeding history, and stent complexity all modulate net clinical benefit. What makes this new trial particularly relevant is its focus on multivessel disease as the defining enrollment criterion, rather than treating it as a post-hoc subgroup. That design choice strengthens the causal inference for this specific population. The central limitation remains the bleeding risk counterweight: extended DAPT consistently elevates rates of clinically significant hemorrhage, meaning absolute benefit must be weighed against individual bleeding scores such as PRECISE-DAPT or HBR criteria. For health-conscious adults with known coronary disease, this reinforces that treatment duration is not a one-size decision — it is a personalized risk calculation that evolving evidence continues to sharpen.